AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates

分组1 - AtriCure reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, and showing improvement from a loss of $0.08 per share a year ago, resulting in an earnings surprise of +400.00% [1] - The company achieved revenues of $140.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.01% and increasing from $124.28 million year-over-year [2] - AtriCure has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 17.5% since the beginning of the year, compared to a decline of 0.1% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at -$0.09 for the coming quarter and $0.02 for the current fiscal year [7] - The Medical - Products industry, to which AtriCure belongs, is currently ranked in the bottom 40% of Zacks industries, which may impact stock performance [8]